Literature DB >> 22457151

Assessment of prognostic factors after primary tumor resection in metastatic colon cancer patients: a Veteran's Affairs Central Cancer Registry (VACCR) analysis, 1995-2008.

Wilson I Gonsalves1, Joseph Wolpert, Tsewang Tashi, Apar K Ganti, Shanmuga Subbiah, Charles Ternent, Peter T Silberstein.   

Abstract

BACKGROUND: Resection of the primary tumor in metastatic colon cancer may occur for palliation of bleeding or obstruction despite distant metastases. This study evaluates clinicopathologic features that serve as prognostic markers in those patients with stage IV colon cancer who undergo resection of their primary tumor.
METHODS: Retrospective analysis of stage IV colon cancer patients who underwent surgical resection of the primary tumor from 1995 to 2008 was done via the Veteran's Affairs Central Cancer Registry. Age, Charlson co-morbidity index score, extent of metastases, sex, number of lymph nodes examined, lymph node ratio (LNR), type of surgery, use of adjuvant chemotherapy, primary tumor site, and grade were studied with respect to overall survival by using log-rank and Kaplan-Meier analysis.
RESULTS: There were 2,625 patients with stage IV colon cancer who had primary tumor resection. Age at diagnosis, Charlson co-morbidity index score, lymph node ratio, and use of chemotherapy were found to be independent predictors of survival by multivariate analysis.
CONCLUSION: Clinicopathologic factors such as LNR, use of chemotherapy, age, co-morbidities, site of primary colon tumor, and number of sites of metastasis are all independent predictors of overall survival in patients who undergo primary colon tumor resection in the metastatic setting.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22457151     DOI: 10.1002/jso.23102

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Benefit of primary tumor resection in stage IV colorectal cancer with unresectable metastasis: a multicenter retrospective study using a propensity score analysis.

Authors:  Soichiro Ishihara; Takeshi Nishikawa; Toshiaki Tanaka; Junichiro Tanaka; Tomomichi Kiyomatsu; Kazushige Kawai; Keisuke Hata; Hioaki Nozawa; Shinsuke Kazama; Hironori Yamaguchi; Eiji Sunami; Joji Kitayama; Kenichi Sugihara; Toshiaki Watanabe
Journal:  Int J Colorectal Dis       Date:  2015-04-29       Impact factor: 2.571

2.  Modern chemotherapy mitigates adverse prognostic effect of regional nodal metastases in stage IV colorectal cancer.

Authors:  Alan A Thomay; David M Nagorney; Steven J Cohen; Elin R Sigurdson; Mark J Truty; Barbara Burtness; Michael J Hall; Yun Shin Chun
Journal:  J Gastrointest Surg       Date:  2013-09-04       Impact factor: 3.452

3.  Palliative primary tumor resection provides survival benefits for the patients with metastatic colorectal cancer and low circulating levels of dehydrogenase and carcinoembryonic antigen.

Authors:  Wen-Zhuo He; Yu-Ming Rong; Chang Jiang; Fang-Xin Liao; Chen-Xi Yin; Gui-Fang Guo; Hui-Juan Qiu; Bei Zhang; Liang-Ping Xia
Journal:  Chin J Cancer       Date:  2016-06-29

4.  Primary tumor location as a predictor of the benefit of palliative resection for colorectal cancer with unresectable metastasis.

Authors:  Rong-Xin Zhang; Wen-Juan Ma; Yu-Ting Gu; Tian-Qi Zhang; Zhi-Mei Huang; Zhen-Hai Lu; Yang-Kui Gu
Journal:  World J Surg Oncol       Date:  2017-07-27       Impact factor: 2.754

5.  Prognostic Impact of Tumor Status, Nodal Status and Tumor Sidedness in Metastatic Colon Cancer.

Authors:  Shiva Kumar R Mukkamalla; Ponnandai Somasundar; Bharti Rathore
Journal:  Cureus       Date:  2020-11-11

6.  A Prognostic Score for Nasopharyngeal Carcinoma with Bone Metastasis: Development and Validation from Multicenter.

Authors:  Chen Chen; Jing-Bo Wu; Hao Jiang; Jin Gao; Jia-Xin Chen; Chang-Chuan Pan; Lu-Jun Shen; Yu Chen; Hui Chang; Ya-Lan Tao; Xiao-Hui Li; Pei-Hong Wu; Yun-Fei Xia
Journal:  J Cancer       Date:  2018-02-12       Impact factor: 4.207

7.  Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.

Authors:  Chen Chen; Yixin Zhou; Xuanye Zhang; Sha Fu; Zuan Lin; Wenfeng Fang; Yunpeng Yang; Yan Huang; Hongyun Zhao; Shaodong Hong; Li Zhang
Journal:  Cancer Med       Date:  2020-01-19       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.